Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Q2 2021 Earnings Presentation

23 slides from Reata Pharmaceuticals's earnings presentation, Aug 9, 2021

  1. Slide 1: 2nd Quarter 2021 Financial Results and Update on Clinical Development Programs

    August 9, 2021 2nd Quarter 2021 Financial Results and Update on Clinical Development Programs Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg

  3. Slide 3: Today's Agenda

    Today’s Agenda Huff, CEO Program Updates | Colin Meyer, MD, Chief R&D Officer Financial & Operational Update| Manmeet Soni, COO & CFO Concluding Remarks | Warren Huff, CEO

  4. Slide 4: Regulatory Update on Omaveloxolone for Patients with Friedreich's ataxia

    Regulatory Update on Omaveloxolone for Patients with Friedreich’s ataxia NDA: New Drug Application

  5. Slide 5: Regulatory Update on Bardoxolone for Patients with Alport Syndrome

    Regulatory Update on Bardoxolone for Patients with Alport Syndrome FDA: U.S. Food and Drug Administration; BIMO: Bioresearch monitoring; PDUFA: Prescription Drug User Fee Act

  6. Slide 6: Mid-Cycle Communication Meeting Overview

    Mid-Cycle Communication Meeting Overview Meeting focused on clinical and statistical topics Four significant issues identified, which we believe are addressable FDA invited us to address these issues in follow up submissions to the NDA Other review topics previously raised were not mentioned FDA did

  7. Slide 7: Chronic Kidney Disease Pipeline

    Chronic Kidney Disease Pipeline

  8. Slide 8: Alport Syndrome

    Alport Syndrome oo; |e Se caroivas | VEAGLE

  9. Slide 9: Mid-Cycle Communication Meeting

    Mid-Cycle Communication Meeting Purpose of the mid-cycle communication meeting is for the FDA to provide Sponsor with a status update on the NDA review, including any issues identified Meeting was focused on four clinical and statistical review issues that were identified as significant Acute PD eff

  10. Slide 10: Off-Treatment Patients who Discontinued Bardoxolone Progressed at Same Rate as Placebo

    4 week Off-Treatment Patients who Discontinued Bardoxolone Progressed at Same Rate as Placebo Patients in Year 2 Study Week Higher rate of eGFR decline in Year 1 explained by patients who discontinued treatment early in the study Acute eGFR increase lost by Week 36 Discontinued patients performed li

  11. Slide 11: Treatment Duration as a Covariate in Week 104 Analysis

    Treatment Duration as a Covariate in Week 104 Analysis FDA questioned, and then acknowledged, that we followed the pre-specified analysis model, which included treatment duration as a covariate During the meeting, we discussed the imputation step, which did not pre-specify use of covariates FDA sugg

  12. Slide 12: Sensitivity Analysis for Off-Treatment Analysis Window Duration

    CARDINAL pre-specified that off-treatment eGFR values be obtained ≥14 days after last dose, supported by PK and off-treatment eGFR data demonstrating resolution of acute eGFR increases occurs within 14 days No association between the magnitude of off-treatment eGFR values and the post-dose period in

  13. Slide 13: Impact of COVID-19

    Impact of COVID-19 FDA stated that COVID-19 did not significantly impact treatment visits, data collection, or study drug dispensation 31% of Week 104 assessments were conducted before COVID-19 and 69% of Week 104 assessments were conducted after COVID-19 FDA noted differences for the pre- and post-

  14. Slide 14: Safety

    Safety FDA did not communicate significant issues about any safety topics FDA communicated that currently no REMS is expected

  15. Slide 15: Bardoxolone in Other Forms of CKD

    Bardoxolone in Other Forms of CKD

  16. Slide 16: FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD

    FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD Phase 3 similar in design to CARDINAL with two-year treatment duration​ Based on experience with CARDINAL NDA submission and recent FDA feedback, we will not unblind FALCON until after study completion We noted that we may not be able to sub

  17. Slide 17: MERLIN Phase 2 Study of Bardoxolone in Patients with CKD at Risk for Rapid Progression

    Phase 2 trial to evaluate the safety and efficacy of bardoxolone in patients at risk of rapidly progressing CKD due to multiple etiologies Multi-center, double-blind, placebo-controlled eGFR 20-60 mL/min​ One of the following UACR ≥ 300 mg/g Annual eGFR decline rate ≥ 4 mL/min Hematuria Primary endp

  18. Slide 18: Financial & Operation Update

    Financial & Operation Update

  19. Slide 19: Q2 2021 Cash & Shares

    Q2 2021 Cash & Shares Cash $755.7M Total Shares Outstanding 36.4M 31.5M class A shares outstanding 4.9M class B shares outstanding 2021 Financial Guidance Based on our operational plans, we anticipate cash runway through mid-2024 Financial Summary 1Excludes stock-based compensation expenses; 2GAAP a

  20. Slide 20: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures

  21. Slide 21: Concluding Remarks

    Concluding Remarks

  22. Slide 22: Reata at a Glance

    Reata at a Glance NDA for bardoxolone in Alport syndrome under review; Mid-cycle communication meeting completed; PDUFA date Feb 2022 FALCON enrolled >370 patients; protocol to be amended FDA granted pre-NDA meeting for omaveloxolone in FA scheduled for Q3 2021; plan to submit NDA during Q1 2022 Upd

  23. Slide 23: Thank you

    Thank you

Reata Pharmaceuticals — Q2 2021 Earnings Presentation on 6ix